share_log

ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) CEO Will Probably Find It Hard To See A Huge Raise This Year

ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) CEO Will Probably Find It Hard To See A Huge Raise This Year

阿卡迪亞製藥公司s(納斯達克股票代碼:ACAD)首席執行官可能會發現今年很難看到大幅加薪
Simply Wall St ·  05/23 18:55

Key Insights

關鍵見解

  • ACADIA Pharmaceuticals to hold its Annual General Meeting on 29th of May
  • CEO Steve Davis' total compensation includes salary of US$856.6k
  • The overall pay is comparable to the industry average
  • Over the past three years, ACADIA Pharmaceuticals' EPS grew by 40% and over the past three years, the total loss to shareholders 27%
  • 阿卡迪亞製藥將於5月29日舉行年度股東大會
  • 首席執行官史蒂夫·戴維斯的總薪酬包括856.6萬美元的工資
  • 總體薪酬與行業平均水平相當
  • 在過去三年中,阿卡迪亞製藥的每股收益增長了40%,在過去三年中,股東的總虧損爲27%

In the past three years, the share price of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has struggled to grow and now shareholders are sitting on a loss. Despite positive EPS growth in the past few years, the share price hasn't tracked the fundamental performance of the company. These are some of the concerns that shareholders may want to bring up at the next AGM held on 29th of May. Voting on resolutions such as executive remuneration and other matters could also be a way to influence management. We discuss below why we think shareholders should be cautious of approving a raise for the CEO at the moment.

在過去的三年中,阿卡迪亞製藥公司(納斯達克股票代碼:ACAD)的股價一直難以增長,現在股東們處於虧損狀態。儘管過去幾年每股收益正增長,但股價並未反映公司的基本表現。這些是股東可能希望在5月29日舉行的下一次股東周年大會上提出的一些問題。對高管薪酬和其他問題等決議進行表決也可能是影響管理層的一種方式。我們在下面討論爲什麼我們認爲股東目前在批准首席執行官的加薪時應謹慎行事。

Comparing ACADIA Pharmaceuticals Inc.'s CEO Compensation With The Industry

比較阿卡迪亞製藥公司。”s 首席執行官向業界提供的薪酬

At the time of writing, our data shows that ACADIA Pharmaceuticals Inc. has a market capitalization of US$2.5b, and reported total annual CEO compensation of US$7.6m for the year to December 2023. Notably, that's a decrease of 46% over the year before. While this analysis focuses on total compensation, it's worth acknowledging that the salary portion is lower, valued at US$857k.

在撰寫本文時,我們的數據顯示,阿卡迪亞製藥公司的市值爲25億美元,並報告稱,截至2023年12月的一年中,首席執行官的年薪總額爲760萬美元。值得注意的是,這比上年下降了46%。儘管該分析側重於總薪酬,但值得承認的是,工資部分較低,爲85.7萬美元。

For comparison, other companies in the American Biotechs industry with market capitalizations ranging between US$2.0b and US$6.4b had a median total CEO compensation of US$8.4m. From this we gather that Steve Davis is paid around the median for CEOs in the industry. What's more, Steve Davis holds US$2.5m worth of shares in the company in their own name.

相比之下,美國生物技術行業中市值介於20億美元至64億美元之間的其他公司的首席執行官總薪酬中位數爲840萬美元。由此我們可以得出結論,史蒂夫·戴維斯的薪水約爲該行業首席執行官的薪水中位數。更重要的是,史蒂夫·戴維斯以自己的名義持有該公司價值250萬美元的股份。

Component 2023 2022 Proportion (2023)
Salary US$857k US$822k 11%
Other US$6.7m US$13m 89%
Total Compensation US$7.6m US$14m 100%
組件 2023 2022 比例 (2023)
工資 857 萬美元 82.2 萬美元 11%
其他 670 萬美元 1300 萬美元 89%
總薪酬 760 萬美元 1400 萬美元 100%

Speaking on an industry level, nearly 24% of total compensation represents salary, while the remainder of 76% is other remuneration. ACADIA Pharmaceuticals sets aside a smaller share of compensation for salary, in comparison to the overall industry. It's important to note that a slant towards non-salary compensation suggests that total pay is tied to the company's performance.

從行業層面來看,總薪酬的近24%代表工資,其餘的76%是其他薪酬。與整個行業相比,阿卡迪亞製藥公司撥出的工資薪酬份額較小。值得注意的是,對非工資薪酬的傾向表明,總薪酬與公司的業績掛鉤。

ceo-compensation
NasdaqGS:ACAD CEO Compensation May 23rd 2024
納斯達克股票代碼:ACAD 首席執行官薪酬 2024 年 5 月 23 日

ACADIA Pharmaceuticals Inc.'s Growth

阿卡迪亞製藥公司。”s 增長

Over the past three years, ACADIA Pharmaceuticals Inc. has seen its earnings per share (EPS) grow by 40% per year. It achieved revenue growth of 56% over the last year.

在過去的三年中,阿卡迪亞製藥公司的每股收益(EPS)每年增長40%。去年,它實現了56%的收入增長。

Overall this is a positive result for shareholders, showing that the company has improved in recent years. It's great to see that revenue growth is strong, too. These metrics suggest the business is growing strongly. Historical performance can sometimes be a good indicator on what's coming up next but if you want to peer into the company's future you might be interested in this free visualization of analyst forecasts.

總體而言,這對股東來說是一個積極的結果,表明公司近年來有所改善。很高興看到收入增長也很強勁。這些指標表明該業務正在強勁增長。歷史表現有時可以很好地衡量接下來會發生什麼,但是如果你想展望公司的未來,你可能會對這種免費的分析師預測可視化感興趣。

Has ACADIA Pharmaceuticals Inc. Been A Good Investment?

阿卡迪亞製藥公司是一項不錯的投資嗎?

Given the total shareholder loss of 27% over three years, many shareholders in ACADIA Pharmaceuticals Inc. are probably rather dissatisfied, to say the least. This suggests it would be unwise for the company to pay the CEO too generously.

鑑於三年內股東總虧損27%,至少可以說,阿卡迪亞製藥公司的許多股東可能相當不滿意。這表明該公司向首席執行官支付過於慷慨的薪水是不明智的。

In Summary...

總而言之...

The fact that shareholders are sitting on a loss on the value of their shares in the past few years is certainly disconcerting. The fact that the stock price hasn't grown along with earnings may indicate that other issues may be affecting that stock. Shareholders would be keen to know what's holding the stock back when earnings have grown. At the upcoming AGM, shareholders will get the opportunity to discuss any issues with the board, including those related to CEO remuneration and assess if the board's plan will likely improve performance in the future.

在過去幾年中,股東的股票價值處於虧損狀態,這一事實無疑令人不安。股價沒有隨着收益的增長而增長,這一事實可能表明其他問題可能正在影響該股票。當收益增長時,股東們會想知道是什麼阻礙了該股的發展。在即將舉行的股東周年大會上,股東將有機會與董事會討論任何問題,包括與首席執行官薪酬有關的問題,並評估董事會的計劃是否有可能改善未來的業績。

If you think CEO compensation levels are interesting you will probably really like this free visualization of insider trading at ACADIA Pharmaceuticals.

如果你認爲首席執行官的薪酬水平很有趣,那麼你可能會非常喜歡阿卡迪亞製藥公司的這種免費的內幕交易可視化。

Of course, you might find a fantastic investment by looking at a different set of stocks. So take a peek at this free list of interesting companies.

當然,通過查看另一組股票,你可能會找到一筆不錯的投資。因此,來看看這份有趣的公司的免費清單吧。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論